The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have metastatic breast cancer. This study is being done to investigate if pelareorep, an oncolytic reovirus (given in combination with chemotherapy [paclitaxel], which is usually given for your type of cancer), and an immunotherapy drug, avelumab, are more effective in treating your type of breast cancer than paclitaxel alone or pelareorep and paclitaxel. Avelumab is approved in the United States for other forms of cancer.
Cohort 1: Paclitaxel (PTX)
Cohort 2: PTX + pelareorep
Cohort 3: PTX + pelareorep + avelumab
The treatment period lasts approximately 16 weeks; however, you may continue to receive study treatment past 16 weeks if you are benefiting from and tolerating the treatment. After treatment the treatment period you will be contacted every 4-6 months to see how you are doing.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to your or your insurance.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04215146